Literature DB >> 32486837

Feasibility of Thorium-227/Radium-223 Gamma-Camera Imaging During Radionuclide Therapy.

Erik Larsson1, Gustav Brolin1, Adriaan Cleton2, Tomas Ohlsson1, Ola Lindén3, Cecilia Hindorf1.   

Abstract

Thorium-227 (227Th) is a long-lived (T1/2 = 18.7 d) α-emitter that has emerged as candidate for radioimmunotherapy. Imaging of patients treated with thorium-227 conjugates is challenging due to the low activity administered and to photon emissions with low yields. In addition, the radioactive daughter radium-223 (223Ra) have photon emissions in the same energy range as 227Th. The long half-life of 223Ra (T1/2 = 11.4 d) and the possibility of redistribution motivates efforts to separate 227Th and 223Ra. The aim of this study was to investigate the feasibility of imaging of patients treated with 227Th-labeled-monoclonal antibody (mAb) and to determine acquisition and image processing parameters to enable discrimination between 227Th and 223Ra. Imaging was performed with a GE Discovery 670 NM/CT γ-camera. Radionuclide separation with different energy windows (EW) and collimators was studied in images of vials with either 227Th or 223Ra. Phantom acquisitions with clinically relevant activities were performed to assess image quality and the usefulness of background subtraction and spatial filtering. Two patients treated with 227Th-labeled-mAb were imaged. Imaging of vials showed that 223Ra can be distinguished from 227Th using multiple energy windows. Medium- and high-energy collimators showed similar performance of sensitivity and spatial resolution, whereas the low-energy collimator had higher sensitivity but poor resolution due to collimator penetration. Visually, the image quality was improved with background subtraction and spatial filtering. The patient images exhibited the expected image quality and a possibility to separate 227Th and 223Ra. γ-Camera imaging of patients treated with 227Th-mAb is feasible and 223Ra can be distinguished from 227Th. Image quality is substantially improved using background subtraction and a spatial smoothing filter. Acquisition settings recommended for planar images are: high-energy general purpose or medium-energy general purpose collimator, 40 min acquisition time and energy windows: (1) 70-100 keV (227Th and 223Ra); (2) 215-260 keV (227Th); (3) 260-290 keV (223Ra); (4) 350-420 keV (223Ra).

Entities:  

Keywords:  radioimmunotherapy; radionuclide therapy; radium-223; thorium-227; γ-camera

Mesh:

Substances:

Year:  2020        PMID: 32486837     DOI: 10.1089/cbr.2019.3516

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

Review 1.  Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.

Authors:  George Sgouros; Eric Frey; Yong Du; Rob Hobbs; Wesley Bolch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-16       Impact factor: 9.236

2.  Quantitative Dual-Isotope Planar Imaging of Thorium-227 and Radium-223 Using Defined Energy Windows.

Authors:  Iain Murray; Bruno Rojas; Jonathan Gear; Ruby Callister; Adriaan Cleton; Glenn D Flux
Journal:  Cancer Biother Radiopharm       Date:  2020-05-19       Impact factor: 3.099

3.  Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes.

Authors:  Nadia Benabdallah; William Scheve; Nicholas Dunn; Delynn Silvestros; Paul Schelker; Diane Abou; Uday Jammalamadaka; Richard Laforest; Zekun Li; Jonathan Liu; David H Ballard; Nichole M Maughan; Hiram Gay; Brian C Baumann; Robert F Hobbs; Buck Rogers; Amir Iravani; Abhinav K Jha; Farrokh Dehdashti; Daniel L J Thorek
Journal:  Theranostics       Date:  2021-09-27       Impact factor: 11.556

4.  Quantitative SPECT/CT imaging of lead-212: a phantom study.

Authors:  Monika Kvassheim; Mona-Elisabeth R Revheim; Caroline Stokke
Journal:  EJNMMI Phys       Date:  2022-08-04

Review 5.  Radionuclides for Targeted Therapy: Physical Properties.

Authors:  Caroline Stokke; Monika Kvassheim; Johan Blakkisrud
Journal:  Molecules       Date:  2022-08-25       Impact factor: 4.927

6.  Why bother with alpha particles?

Authors:  A Paden King; Frank I Lin; Freddy E Escorcia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-27       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.